ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
28 announcements with these filters
The company held its 30th Annual General Meeting on September 25, 2026. Shareholders considered and approved items including financial statements and director re-appointments.
CRISIL Ratings upgraded Tatva Chintan's long-term bank facilities to CRISIL A-/Stable and short-term facilities to CRISIL A2+. This upgrade reflects the company's improved credit profile.
Tatva Chintan Pharma Chem Limited submitted its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26. The report highlights its specialty chemicals operations and ESG metrics.
Tatva Chintan Pharma Chem Limited has submitted its Annual Report for the financial year 2025-26. The company's 30th Annual General Meeting is scheduled for September 25, 2026.
Tatva Chintan Pharma Chem Limited has scheduled its 30th Annual General Meeting for September 25, 2026. Key agenda items include dividend declaration and director re-appointments.
Tatva Chintan Pharma Chem Limited scheduled its 30th AGM for September 25, 2026. Key agenda items include dividend declaration and increasing borrowing limits to ₹1,000 Crore.
Tatva Chintan Pharma Chem announced the resignation of Mr. Ajay Rawat, Assistant Vice President – Research and Development, effective from November 13, 2026.
Tatva Chintan Pharma Chem Limited is communicating the process for TDS on the final dividend for FY 2025-26 to its shareholders. Shareholders are required to submit necessary tax declarations by 10 September 2026.
Tatva Chintan reported strong Q1 FY27 results with 43% YoY revenue growth. Strategy focuses on expanding SDA for Euro 7 standards and commercializing new pharma/semiconductor molecules.
Tatva Chintan Pharma Chem held a groundbreaking ceremony for a new greenfield manufacturing unit at Dahej-III, Gujarat. This expansion supports the company's long-term growth strategy.
Tatva Chintan Pharma Chem re-appointed Chintan Shah as MD, and Ajaykumar Patel and Shekhar Somani as WTDs. All appointments are for 36-month terms starting February 2027.
Tatva Chintan reported strong Q1FY27 performance with 43% YoY revenue growth to ₹1,671 Mn. Strategy focuses on green chemistry, R&D in continuous flow, and electrolysis for SDAs.
Tatva Chintan approved a Rs. 200 Crore greenfield expansion at Dahej-III, adding 344 KL reactor capacity. The board also re-appointed key directors and reported quarterly results.
Tatva Chintan Pharma Chem Ltd will hold a Board meeting on 17 July 2026 to approve Q2 2026 results. Trading window closes from 1 July for 48 hours.
Tatva Chintan reported Q4 FY26 revenue of ₹1,341 million (up 24% YoY) and EBITDA of ₹281 million (up 214% YoY), driven by improved product mix and operating leverage.
Tatva Chintan Pharma Chem Limited submitted its Annual Secretarial Compliance Report for FY26. The auditor confirmed total compliance with SEBI listing regulations and guidelines.
Tatva Chintan reported FY26 revenue of ₹5,059 Mn, up 32% YoY. Growth driven by SDA segment expansion and 'green' chemistry adoption.
Tatva Chintan reported a strong FY26 with revenue up 32% to ₹5,059 Mn and PAT surging 636% to ₹421 Mn. Growth driven by SDA and PASC segments.
Tatva Chintan Pharma Chem Ltd reported revenue from operations of ₹134.1 Cr (+24.3% YoY) and net profit of ₹10.3 Cr (+930.0% YoY) for Q4 FY26.
Tatva Chintan Pharma Chem reported audited FY26 results and recommended a Rs. 2 per share dividend. Consolidated annual profit reached ₹42.05 Crore on ₹509.41 Crore revenue.
Tatva Chintan Pharma Chem recommended a final dividend of ₹2 per equity share for FY 2025-26. The record date will be announced in due course.
Tatva Chintan Pharma's board re-appointed RSM Astute and Zarna Thakar & Associates as auditors. The appointments are effective from April 2026 for twelve months.
Tatva Chintan shows signs of a turnaround with 24% YoY revenue growth, though high raw material costs and geopolitical disruptions in the Middle East persist as headwinds.
Tatva Chintan Pharma Chem Ltd has scheduled a board meeting on 16 May 2026. The directors will consider auditing the FY2026 financial results and recommending a final dividend. The trading window for designated persons remains closed until 48 hours after results are publicized.
Tatva Chintan Pharma Chem Limited submitted its annual disclosure for FY 2025-26, confirming it does not meet the criteria for classification as a 'Large Corporate' under SEBI debt-raising norms. The company reported nil incremental borrowing and mandatory debt issuance requirements for the current block.
Tatva Chintan Pharma Chem Limited confirmed it is not classified as a Large Corporate under SEBI debt-raising norms. As of March 31, 2026, the company reported outstanding borrowings of ₹6.04 Crore. The company maintains a long-term credit rating of CRISIL BBB+/Stable and a short-term rating of CRISIL A2.
Tatva Chintan Pharma Chem Ltd reported net profit of ₹15.2 Cr (+15100.0% YoY) for Q3 FY26.
Tatva Chintan Pharma Chem Limited submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (DP) Regulations for the period ended March 31, 2026. The certificate from MUFG Intime India confirms that security certificates received for dematerialisation were processed and cancelled within prescribed timelines.